therapeutic action: ergosterol synthesis inhibition

Clinical aspects and recent advances in fungal diseases impacting human health

Fungal infections are increasingly common health threats affecting over a billion people worldwide, ranging from minor allergies to serious life-threatening infections. The biggest problems are that fungi are becoming resistant to current medications, diagnosis can be difficult and slow, and treatment options are limited. Recent developments include new antifungal drugs like ibrexafungerp and rezafungin that work differently from older medications, offering hope for treating resistant infections. Better awareness among doctors and patients, faster diagnostic methods, and responsible use of antifungals are essential to combat this growing public health challenge.

Read More »

Healthcare-associated fungal infections and emerging pathogens during the COVID-19 pandemic

During the COVID-19 pandemic, fungal infections became a serious complication in hospitalized patients, especially those receiving steroids and other immune-suppressing treatments. Common fungal pathogens like Candida and Aspergillus caused dangerous coinfections, with infection rates varying significantly by region. Current antifungal medications have significant limitations including toxicity and resistance, highlighting the urgent need for new and safer antifungal treatments.

Read More »

Clinical aspects and recent advances in fungal diseases impacting human health

Fungal infections are becoming a major health threat, affecting over a billion people worldwide. The main problems are difficulty diagnosing these infections, increasing resistance to current medications, and limited treatment options. Doctors and the public need better awareness, and new antifungal drugs with different approaches are needed to effectively treat resistant infections.

Read More »
Scroll to Top